Executive Assistant

Company hidden

Watertown, Massachusetts, United States Full-time Posted 12d ago

The company is currently advancing its lead program, ACR-368 (also known as prexasertib), a selective small molecule inhibitor targeting CHK1 and CHK2 in a potentially registrational Phase 2 trial for EC. The company has received Fast Track designation from the Food and Drug Administration, or FDA, for the investigation of ACR-368 as a monotherapy based on OncoSignature-predicted sensitivity in patients with EC. The FDA has granted a Breakthrough Device designation for the ACR-368 OncoSignature assay for the identification of patients with endometrial cancer who may benefit from ACR-368…

See the company and apply

Unlock to see who’s hiring, read the full description and apply on the company site.

Checking access…

See how well you match this job

Upload your resume and we’ll score your fit for this role and 6 similar roles — then tailor your CV to it with AI. Free, no credit card.

Check your match

Similar jobs

Explore related jobs

Want more roles like this? Browse fresh jobs or tailor your resume with AI.